NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a ...
(NEW YORK) — Pfizer announced Thursday that its vaccine candidate for respiratory syncytial virus was more than 85% effective in preventing lower respiratory tract illness in older adults. The New ...
2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- New research on Neurogenic Bladder is the subject of a report. According to news reporting out of Tokyo, Japan, ...
Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer (PFE) is running a Phase 2 study titled “AN ...
Analyses from RWD program, ACROPOLIS, use two large U.S. databases to provide insights on Eliquis ® (apixaban), warfarin, and other direct oral anticoagulants in patients with NVAF at 2017 American ...
There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on ...
Pfizer's deliberations, which previously have not been disclosed, offer a rare window into the frustrating search for Alzheimer's treatments inside one of the world's largest drug companies. Despite ...
Additionally, on December 17, Pfizer and Astellas announced positive topline results from the Phase 3 EV-304 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback